180 Life Sciences Corp (ATNF)
1.54
-0.07
(-4.35%)
USD |
NASDAQ |
Jul 05, 14:52
180 Life Sciences SG&A Expense (TTM): 8.241M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 8.241M |
December 31, 2023 | 10.69M |
September 30, 2023 | 14.26M |
June 30, 2023 | 15.24M |
March 31, 2023 | 16.50M |
December 31, 2022 | 15.47M |
September 30, 2022 | 12.90M |
June 30, 2022 | 13.09M |
March 31, 2022 | 12.09M |
Date | Value |
---|---|
December 31, 2021 | 11.69M |
September 30, 2021 | 10.76M |
June 30, 2021 | 7.389M |
March 31, 2021 | 4.873M |
December 31, 2020 | 3.355M |
September 30, 2020 | 19.86M |
June 30, 2020 | 19.86M |
March 31, 2020 | 19.65M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
3.355M
Minimum
Dec 2020
19.86M
Maximum
Sep 2020
12.70M
Average
12.90M
Median
Sep 2022
SG&A Expense (TTM) Benchmarks
Seelos Therapeutics Inc | 11.62M |
Oragenics Inc | 5.999M |
Rezolute Inc | 13.97M |
GT Biopharma Inc | 7.409M |
IGM Biosciences Inc | 47.61M |